Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk – a preliminary study

References

• Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., … Taylor, D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (New York, N.Y.), 329(5996), 1168–1174. doi:10.1126/science.1193748
   PubMed Web of Science ®Google Scholar
• Aghaizu, A., Mercey, D., Copas, A., Johnson, A. M., Hart, G., & Nardone, A. (2013). Who would use PrEP? Factors associated with intention to use among MSM in London: A community survey. Sexually Transmitted Infections, 89, 207–211. doi: 10.1136/sextrans-2012-050648
   PubMed Web of Science ®Google Scholar
• Aids Fonds. (2014). Inzet van PrEP in Nederland. Aids Fonds. Retrieved from www.aidsfonds.nl/nieuws/inzet-van-prep-in-NL
   Google Scholar
• Anton, P. A., Saunders, T., Elliott, J., Khanukhova, E., Dennis, R., Adler, A., …  McGowan, I. (2011). First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PloS One, 6(9). doi:10.1371/journal.pone.0023243
   Web of Science ®Google Scholar
• Baeten, J. M., Donnell, D., Mugo, N. R., Ndase, P., Thomas, K. K., Campbell, J. D., … Celum, C. (2014). Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: An update of data from a randomised, double-blind, phase 3 trial. Lancet Infectious Disease, 14(11), 1055–1064. doi: 10.1016/S1473-3099(14)70937-5
   PubMed Web of Science ®Google Scholar
• Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., … Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine, 367(5), 399–410. doi:10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Barash, E. A., & Golden, M. (2010). Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care and STDs, 24(11), 689–691. doi:10.1089/apc.2010.0173
   PubMed Web of Science ®Google Scholar
• Baron, D., Djordjevic, M., & Majija, L. (2015). HIV prevention study does not confirm tenofovir gel effectiveness – Women require convenient and effective HIV prevention methods that work within the context of their lives. FACTS Consortium. Retrieved from http://www.avac.org/sites/default/files/u3/FACTSResults.pdf
   Google Scholar
• Beyrer, C., Baral, S. D., van Griensven, F., Goodreau, S. M., Chariyalertsak, S., Wirtz, A. L., & Brookmeyer, R. (2012). Global epidemiology of HIV infection in men who have sex with men. The Lancet, 380(9839), 367–377. Retrieved from http://www.sciencedirect.com/science/article/pii/S0140673612608216 doi: 10.1016/S0140-6736(12)60821-6
   PubMed Web of Science ®Google Scholar
• Canadian HIV Trials Network. (2014). Ipergay. Retrieved from www.hivnet.ubc.ca
   Google Scholar
• Carballo-Diéguez, A., Exner, T., Dolezal, C., Pickard, R., Lin, P., & Mayer, K. H. (2007). Rectal microbicide acceptability: Results of a volume escalation trial. Sexually Transmitted Diseases, 34(4), 224–229. doi:10.1097/01.olq.0000233715.59239.83
   PubMed Web of Science ®Google Scholar
• Carballo-Diéguez, A., Giguere, R., Dolezal, C., Bauermeister, J., Leu, C.-S., Valladares, J., … McGowan, I. (2014). Rectal-specific microbicide applicator: Evaluation and comparison with a vaginal applicator used rectally. AIDS and Behavior, 18(9), 1734–1745. doi:10.1007/s10461-014-0793-0
   PubMed Web of Science ®Google Scholar
• Cassell, M. M., Halperin, D. T., Shelton, J. D., & Stanton, D. (2006). Risk compensation: The Achilles’ heel of innovations in HIV prevention? BMJ (Clinical Research Ed.), 332(7541), 605–607. doi:10.1136/bmj.332.7541.605
   PubMed Web of Science ®Google Scholar
• Chimi, C. J., & Russell, D. L. (2009). The Likert scale : A proposal for improvement using quasi-continuous variables. Proc ISECON, 26(2), 1–10.
   Google Scholar
• Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Vanichseni, S. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 381(9883), 2083–2090. doi:10.1016/S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• Dezzutti, C. S., Rohan, L. C., Wang, L., Uranker, K., Shetler, C., Cost, M., … Friend, D. (2012). Reformulated tenofovir gel for use as a dual compartment microbicide. The Journal of Antimicrobial Chemotherapy, 67(9), 2139–2142. doi:10.1093/jac/dks173
   PubMed Web of Science ®Google Scholar
• Elford, J., Bolding, G., Davis, M., Sherr, L., & Hart, G. (2004). Web-based behavioral surveillance among men who have sex with men: A comparison of online and offline samples in London, UK. Journal of Acquired Immune Deficiency Syndromes (1999), 35(4), 421–426. doi: 10.1097/00126334-200404010-00012
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. (2014). Pre-exposure prophylaxis for HIV in Europe. European Centre for Disease Prevention and Control. Retrieved from http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=774
   Google Scholar
• Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599. doi:10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Hankins, C. A., & Dybul, M. R. (2013). The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: A review. Current Opinion in HIV and AIDS, 8(1), 50–58. doi:10.1097/COH.0b013e32835b809d
   PubMed Web of Science ®Google Scholar
• HIV Prevention Trials Network. (2014a). HPTN 069: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for pre-exposure prophylaxis (PrEP) to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. HIV Prevention Trials Network. Retrieved from http://www.hptn.org/research_studies/hptn069.asp
   Google Scholar
• HIV Prevention Trials Network. (2014b). HPTN 076: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP). HIV Prevention Trials Network. Retrieved from http://www.hptn.org/research_studies/hptn076.asp
   Google Scholar
• Hochbaum, G. M. (1958). Public participation in medical screening programs; A socio-psychological study.
   Google Scholar
• International Partnership for Microbicides. (2014). International partnership for microbicides – The ring study. IPM. International Partnership for Microbicides. Retrieved February 13, 2013, from http://www.ipmglobal.org/the-ring-study
   Google Scholar
• Keuzenkamp, S., Kooiman, N., & Van Lisdonk, J. (2012). Niet te ver uit de kast – Ervaringen van homo- en biseksuelen in Nederland.
   Google Scholar
• Krakower, D. S., Mimiaga, M. J., Rosenberger, J. G., Novak, D. S., Mitty, J. A., White, J. M., & Mayer, K. H. (2012). Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PloS One, 7(3), e33119. doi:10.1371/journal.pone.0033119
   PubMed Web of Science ®Google Scholar
• Lorente, N., Fugon, L., Carrieri, M. P., Andreo, C., Molina, J., & Spire, B. (2012). HIV acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care: Psychological and Socio-Medical Aspects of AIDS/HIV, 24(4), 37–41.
   Google Scholar
• Marcus, J. L., Glidden, D. V., Mayer, K. H., Liu, A. Y., Buchbinder, S. P., Amico, K. R., … Grant, R. M. (2013). No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. PLoS ONE, 8(12), e81997. doi:10.1371/journal.pone.0081997
   PubMed Web of Science ®Google Scholar
• Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., … Chirenje, Z. M. (2015). Tenofovir-based preexposure prophylaxis for HIV Infection among African Women. The New England Journal of Medicine, 372(6), 509–518. doi:10.1056/NEJMoa1402269
   PubMed Web of Science ®Google Scholar
• McCormack, S., & Dunn, D. (2015). Pragmatic open-label randomised trial of preexposure PROPHYLAXIS: The PROUD Study. In CROI. p. 89.
   Google Scholar
• McGowan, I. (2014). The development of rectal microbicides for HIV prevention. Expert Opinion on Drug Delivery, 11(1), 69–82. doi: 10.1517/17425247.2013.860132
   PubMed Web of Science ®Google Scholar
• McKenzie, A. (2014). Ipergay MTL. Retrieved from http://www.ipergaymtl.com/
   Google Scholar
• Medical Research Council U. (2015). The PROUD study: Examining the impact on gay men of using pre-exposure prophylaxis (PrEP). Medical Research Council U. Retrieved from http://www.proud.mrc.ac.uk/
   Google Scholar
• Microbicides Trials Network. (2013). Researchers launch first-ever phase II safety study of a rectal microbicide to prevent HIV. Microbicide Trials Network. Retrieved from http://www.mtnstopshiv.org/node/5193
   Google Scholar
• Microbicides Trials Network. (2014a). ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women. Microbicide Trials Network. Retrieved from http://www.mtnstopshiv.org/node/5862
   Google Scholar
• Microbicides Trials Network. (2014b). MTN-017: Phase II safety and acceptability study of tenofovir gel reformulated for rectal use. MTN. Retrieved from http://wwwmtnstopshiv.org/news/studies/mtn017/backgrounder
   Google Scholar
• Mimiaga, M. J., Case, P., Johnson, C. V., Safren, S. A., & Mayer, K. H. (2010). Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. Journal of Acquired Immune Deficiency Syndrome, 50(1), 77–83. doi:10.1097/QAI.0b013e31818d5a27
   Web of Science ®Google Scholar
• Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Chidiac, C., Charreau, I., … Delfraissy, J.-F. (2015). On demand PrEP with oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. In CROI. pp. 89–90.
   Google Scholar
• Mugwanya, K. K., Donnell, D., Celum, C., Thomas, K. K., Ndase, P., Mugo, N., … Baeten, J. M. (2013). Sexual behavior of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: A longitudinal analysis. Lancet Infectious Disease, 13(12), 1021–1028. doi:10.1016/S1473-3099(13)70226-3
   PubMed Web of Science ®Google Scholar
• Munro, S., Lewin, S., Swart, T., & Volmink, J. (2007). A review of health behaviour theories: How useful are these for developing interventions to promote long-term medication adherence for TB and HIV/AIDS? BMC Public Health, 7, 104. doi:10.1186/1471-2458-7-104
   PubMed Web of Science ®Google Scholar
• Neff, P. C., Kurisu, T., Ndolo, T., Fox, K., & Akkina, R. (2011). A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PloS One, 6(6), e20209. doi:10.1371/journal.pone.0020209
   PubMed Web of Science ®Google Scholar
• Peinado, J., Lama, J. R., Galea, J. T., Segura, P., Casapia, M., Ortiz, A., … Sánchez, J. (2013). Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Peru. Journal of the International Association of Physicians in AIDS Care, 1–6. doi:10.1177/1545109712473650
   Google Scholar
• Poynten, I. M., Jin, F., Prestage, G. P., Kaldor, J. M., Imrie, J., & Grulich, a E. (2010). Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. HIV Medicine, 11(4), 282–288. doi:10.1111/j.1468-1293.2009.00777.x
   PubMed Web of Science ®Google Scholar
• Public Health England. (2014). PROUD. Retrieved from www.proud.mrc.ac.uk
   Google Scholar
• Rhodes, S. D., Bowie, D. A, & Hergenrather, K. C. (2003). Collecting behavioural data using the world wide web: Considerations for researchers. Journal of Epidemiology and Community Health, 57(1), 68–73. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1732282&tool=pmcentrez&rendertype=abstract doi: 10.1136/jech.57.1.68
   PubMed Web of Science ®Google Scholar
• Stichting HIV Monitoring. (2012). Monitoring report 2012 – Human immunodeficiency virus (HIV) infections in the Netherlands. p. 191.
   Google Scholar
• Stretcher, V., & Rosenstock, I. M. (1997). Health behavior and health education: Theory, research and practice. The health belief model.
   Google Scholar
• Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A, Smith, D. K., Rose, C. E., Segolodi, T. M., … Brooks, J. T. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. The New England Journal of Medicine, 367(5), 423–434. doi:10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Turner, L. W., Hunt, S. B., DiBrezzo, R., & Jones, C. (2004). Health belief model. Retrieved from http://www.jblearning.com/samples/0763743836/chapter4.pdf
   Google Scholar
• US Food and Drug Administration [Internet]. (2012). Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. Retrieved from http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm312264.htm
   Google Scholar
• Van de Mortel, T. F. (2008). Faking it : Social desirability response bias in self-report research. Australian Journal of Advanced Nursing, 25(4), 40–48.
   Web of Science ®Google Scholar
• Van der Straten, A., Van Damme, L., Haberer, J. E., & Bangsberg, D. R. (2012). Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (London, England), 26(7), F13–F19. doi:10.1097/QAD.0b013e3283522272
   PubMed Web of Science ®Google Scholar
• Young, I., Li, J., & McDaid, L. (2013). Awareness and willingness to use HIV Pre-exposure Prophylaxis amongst gay and bisexual men in Scotland: Implications for biomedical HIV prevention. PLoS One, 8, e64038. doi: 10.1371/journal.pone.0064038
   Google Scholar